גידולים נוירואנדוקריניים (NET)

מחקר בסיסי:

The effect of mTOR inhibitors in combination with autophagy inhibitors on NET cells - as a new possibile effective therapy to overcome treatment resistance for NET patients.
Positive modulation of Expression of the type 2 somatostatin Receptor (SSTR2) in tumors of patients with NETs - a means towards improving therapy with somatostatin analogues.

מחקר קליני:

TELESTAR and TELECAST studies, two international phase III double - blind placebo-controlled studies aiming to assess the possible efficacy of a new drug called telotristat ethyl (a serotonin synthesis inhibitor) in patients who have symptoms of carcinoid syndrome that are not controlled with other drugs (completed).
A double blind, phase III trial comparing cabozantinib (a tyrosine kinase inhibitor) with placebo in patients with progressive metastatic medullary thyroid carcinoma, to assess progression-free survival (PFS).

פרסומים:

פרופ' סימונה גלסברג, MD:

פרופ' דוד גרוס, MD:

ד"ר שני אבניאל-פולק, PhD:

ד"ר קירה אולייניקוב, MD:

https://pubmed.ncbi.nlm.nih.gov/?term=Oleinikov+Kira